Bruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX Acquisition

Benzinga·08/17/2023 16:41:30

Listen to the news

Bruker Corporation (NASDAQ:BRKR) has agreed to acquire PhenomeX Inc (NASDAQ:CELL) for $1.00 per share in an all-cash transaction.

The proposed acquisition values PhenomeX at a total equity value of approximately $108 million.

PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages.

PhenomeX was formed in early 2023 through the combination of Berkeley Lights and IsoPlexis, and PhenomeX currently has an installed base of more than 400 instruments.

PhenomeX provides instruments, software, and molecular biology reagents for single-cell biology workflows.

The PhenomeX products include the key Beacon Optofluidic platform and the IsoLight and IsoSpark proteomics barcoding platform.

Recently, PhenomeX released Q2 earnings reporting Q2 total revenue of $14.1 million, with $7.3 million in recurring revenue.

Placed five platforms, including selling the first Beacon QuestTM, bringing the total PhenomeX installed base to 435 placements.

The transaction is expected to close in the fourth quarter of 2023. After the tender offer closes, PhenomeX will merge into a wholly-owned subsidiary of Bruker.

Price Action: CELL shares are up 134.82% at $0.94, and BRKR shares are down 0.49% at $65.38 on the last check Thursday.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English